Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POMREP: Zoledronic acid vs placebo in pediatric CRMO resistant to NSAIDs
2023-506420-93-00Phase 2Authorised
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic recurrent multifocal osteomyelitis (CRMO) comparing Zoledronic acid with Placebo (2 arms). Primary endpoint: Change in standardized pain score from baseline to week 12. Planned start May 2026; status: authorised.
02
Drugs
zoledronic acid
03
Conditions
chronic recurrent multifocal osteomyelitis (CRMO)
Beyond the preview
Go deeper on 2023-506420-93-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-506420-93-00.